Fintel on MSN1d
Leerink Partners Initiates Coverage of Zura Bio (ZURA) with Outperform Recommendation
Fintel reports that on November 4, 2024, Leerink Partners initiated coverage of Zura Bio (NasdaqCM:ZURA) with a Outperform ...
bovnews3h
Stock Shock: The Unpredictable Rise and Fall of NVST—What’s Driving the Drama?
On Monday, Envista Holdings Corp (NVST) stock saw a modest uptick, ending the day at $21.28 which represents a slight increase of $0.34 or 1.62% from the prior close of $20.94. The stock opened at $21 ...
fintechmagazine5d
Leerink: The Company That Bounced Back from an SVB Demerger
Leerink Partners CIO Jeff Gerson on how the firm realigned its technology strategies and services after it demerged from SVB ...
Molecular Partners’ Promising Pipeline and Financial Stability Justify Buy Rating
In a report released on November 1, Jonathan Chang from Leerink Partners reiterated a Buy rating on Molecular Partners (MOLN – Research ...
bovnews1d
Leerink Partners Just Upgraded Gilead Sciences, Inc. (GILD) Stock—What Does This Mean for Investors?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...
fintechmagazine5d
Jeff Gerson
Leerink Partners CIO Jeff Gerson on how the firm realigned its technology strategies and services after it demerged from SVB ...
Yahoo Finance4d
Tom Davidson Joins Leerink Partners as Co-President and Co-Head of Global Investment Banking
BOSTON, Nov. 1, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce that Tom Davidson has joined as Co-President of the firm and Co ...
ETF Daily News8d
Leerink Partners Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)
Leerink Partners initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a report released on Thursday morning, MarketBeat Ratings reports. The firm issued an outperform ...
Leerink Partners Boosts Aquestive Therapeutics (NASDAQ:AQST) Price Target to $13.00
Aquestive Therapeutics (NASDAQ:AQST – Free Report) had its price target raised by Leerink Partners from $12.00 to $13.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an ...
Seeking Alpha5d
Envista upgraded to market perform by Leerink, management cited
Leerink upgraded Envista (NYSE:NVST) to market perform from underperform, citing management’s efforts to stabilize performance. The investment bank said its biggest concern had been the company ...
BioSpace6d
Lilly Hit With Lower-Than-Expected Mounjaro and Zepbound Q3 Sales, Narrows Full-Year Forecast
Eli Lilly’s blockbuster weight loss and diabetes drugs missed analysts’ expectations by 18% in the third quarter, which were ...
MedCity News6d
Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder
Sage said Zulresso will be commercially available until Dec. 31. In a note sent to investors, Leerink Partners analyst Marc Goodman said the discontinuation of further development of Zurzuvae in ...